5-Jun-2026
Insmed Insiders Make Major Moves in High-Value Stock Sell-Off
TipRanks (Fri, 5-Jun 10:01 PM ET)
Analysts’ Top Healthcare Picks: Zenas BioPharma, Inc. (ZBIO), Insmed (INSM)
TipRanks (Fri, 5-Jun 1:31 PM ET)
Nasdaq-100 falls more than 3% as Arm, AMD, and Micron lead the broad tech selloff
Seeking Alpha News (Fri, 5-Jun 1:10 PM ET)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PRNewswire (Thu, 4-Jun 7:00 AM ET)
UBS Sticks to Their Buy Rating for Insmed (INSM)
TipRanks (Thu, 4-Jun 6:36 AM ET)
TipRanks (Thu, 4-Jun 6:30 AM ET)
JPMorgan Says Buy the Dip in These 2 Large-Cap Biotech Stocks
TipRanks (Thu, 4-Jun 5:30 AM ET)
William Blair updates its Conviction List
Seeking Alpha News (Tue, 2-Jun 5:19 AM ET)
Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
PRNewswire (Wed, 27-May 7:00 AM ET)
Insmed Delivers Strong First-Quarter Revenue Growth as BRINSUPRI Momentum Accelerates
Market Chameleon (Thu, 7-May 3:45 AM ET)
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Insmed trades on the NASDAQ stock market under the symbol INSM.
As of June 5, 2026, INSM stock price declined to $94.22 with 7,574,738 million shares trading.
INSM has a beta of 0.08, meaning it tends to be less sensitive to market movements. INSM has a correlation of 0.00 to the broad based SPY ETF.
INSM has a market cap of $20.42 billion. This is considered a Large Cap stock.
Last quarter Insmed reported $306 million in Revenue and -$.76 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.22.
In the last 3 years, INSM traded as high as $212.75 and as low as $18.77.
The top ETF exchange traded funds that INSM belongs to (by Net Assets): VTI, QQQ, VB, VXF, VO.
INSM has outperformed the market in the last year with a return of +29.5%, while the SPY ETF gained +25.6%. However, in the most recent history, INSM shares have underperformed the stock market with its stock returning -34.4% in the last 3 month period and -11.3% for the last 2 week period, while SPY has returned +8.5% and -1.1%, respectively.
INSM support price is $101.16 and resistance is $108.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INSM shares will trade within this expected range on the day.